Biotech industry news

Biotech industry news. Deduplicated factual headlines, scored for importance, with entity sentiment and the companies, sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-30 13:53:00 UTC#546134updateconfirmednews

Acumen Pharmaceuticals halts development of lead Alzheimer's drug sabirnetug after Phase 2 failure, explores strategic options

dow_jonesimportance 0.70trust 0.90Acumen Pharmaceuticals, Inc. -0.90sabirnetug -0.90Alzheimer's disease -0.20

2026-10-30 13:23:00 UTC#545897newconfirmednews

Pelthos to acquire Castle Creek Biosciences in merger with $57.5M+ PIPE financing

tradingviewimportance 0.60trust 0.80Pelthos Therapeutics +0.40Castle Creek Biosciences, Inc. +0.40Paragon Biosciences, LLC +0.20+1 entities

2026-10-30 12:47:55 UTC#545664newconfirmednews

Acumen Pharmaceuticals shares drop following mid-stage clinical trial setback for Alzheimer's drug candidate

seeking alphaimportance 0.60trust 0.70Acumen Pharmaceuticals, Inc. -0.80

2026-10-30 10:32:19 UTC#544643updateconfirmeddata release

Regeneron Pharmaceuticals Q3 2026 Non-GAAP EPS $20.07 beats by $3.82, Revenue $5.1B beats by $540M

seeking alphaimportance 0.70trust 0.90Regeneron Pharmaceuticals, Inc. +0.80

2026-10-30 10:30:00 UTC#544590updateconfirmeddata release

Regeneron Pharmaceuticals reports Q3 2026 revenue of $5.12 billion

dow_jonesimportance 0.50trust 0.90Regeneron Pharmaceuticals, Inc. +0.30

2026-10-30 10:30:00 UTC#544583newconfirmeddata release

Regeneron Pharmaceuticals reports Q3 2026 EPS of $18.45

dow_jonesimportance 0.60trust 0.90Regeneron Pharmaceuticals, Inc. 0

2026-10-30 09:29:18 UTC#544254newconfirmednews

UK MHRA approves Casgevy gene-editing treatment for children with sickle-cell and beta-thalassemia

reutersimportance 0.60trust 0.90Medicines and Healthcare products Regulatory Agency 0Casgevy +0.60

2026-10-30 09:01:52 UTC#544234updateconfirmednews

Genmab A/S market value increases by $10 billion this week following positive petosemtamab trial data

bloombergimportance 0.50trust 0.90Genmab A/S +0.80

2026-10-30 07:30:00 UTC#543547newconfirmednews

Oncopeptides AB completes 50M share directed issue, total shares increase to 445.29M

tradingviewimportance 0.50trust 0.80Oncopeptides AB -0.40

2026-10-30 05:01:25 UTC#542822newconfirmednews

Ligand Pharmaceuticals raises 2026 adjusted EPS guidance to $9.50-$9.75, targets $200M annual capital deployment

seeking alphaimportance 0.50trust 0.70Ligand Pharmaceuticals Incorporated +0.50

2026-10-30 04:59:51 UTC#542813updateconfirmednews

Gilead Sciences updates 2026 sales guidance to $30.7B-$31.0B, details $1.5B 2028 Biktarvy revenue impact

seekingalpha.comimportance 0.60trust 0.80Gilead Sciences, Inc. +0.40Daniel O'Day 0Biktarvy -0.40+2 entities

2026-10-30 03:09:34 UTC#542466updateconfirmednews

PTC Therapeutics projects 2026 product revenue of $960M-$990M, targets Q4 2026 for ST-920 filing

seeking alphaimportance 0.50trust 0.70PTC Therapeutics, Inc. +0.40Sephience +0.30ST-920 +0.30

2026-10-30 02:15:48 UTC#542295newconfirmedpress release

Aspen Neurosciences prices initial public offering of 9.375 million shares at $15.00 per share

reutersimportance 0.50trust 0.90Aspen Neurosciences, Inc. 0

2026-10-30 01:00:00 UTC#542053newconfirmedpress release

Phrontline Biopharma reports positive Phase Ia data for TJ101 in urothelial carcinoma, initiates Phase Ib trial

pr newswireimportance 0.50trust 0.90Phrontline Biopharma +0.60TJ101 +0.60European Society for Medical Oncology 0

2026-10-30 00:40:51 UTC#541992updateconfirmednews

BridgeBio sets BBP-418 PDUFA for Nov 27 and infigratinib PDUFA for Feb 4, 2027

seeking alphaimportance 0.50trust 0.70BridgeBio Pharma, Inc. +0.40BBP-418 +0.40infigratinib +0.40

2026-10-30 00:15:00 UTC#541903newconfirmedpress release

Bambusa Therapeutics prices upsized IPO of 10.56 million shares at $16.00 per share

pr_newswireimportance 0.60trust 1.00Bambusa Therapeutics, Inc. +0.30

2026-10-30 00:01:02 UTC#541875updateconfirmednews

Novocure updates 2026 revenue guidance to $736M-$743M and adjusted EBITDA to $24M-$34M

seeking alphaimportance 0.50trust 0.80Novocure Limited +0.20

2026-10-29 23:30:03 UTC#541757newconfirmednews

Helix BioPharma FY26 net loss $3.35M; R&D spending cut 54% as company warns of insufficient cash runway

tradingviewimportance 0.60trust 0.70Helix BioPharma Corp. -0.70

2026-10-29 21:09:39 UTC#540962newconfirmednews

Gilead Sciences widens 2026 non-GAAP loss forecast despite Q3 earnings beat

seeking alphaimportance 0.60trust 0.70Gilead Sciences, Inc. -0.40

2026-10-29 21:01:09 UTC#540904updateconfirmeddata release

NovoCure Limited Q3 adjusted loss $0.09/share vs $0.24/share est; revenue $193.40M vs $182.23M est

reutersimportance 0.60trust 0.90NovoCure Limited +0.40